Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD)‎ Refractory to Ranibizumab

الملخص EN

Purpose.

To evaluate the response of intravitreal aflibercept injection (IAI) in eyes with detachment of retinal pigment epithelium (DEP) secondary to nAMD refractory to monthly ranibizumab.

Patients and Methods.

This is a retrospective, multicenter study.

All patients received 3 IAI then treated as needed every 4 weeks for 12 months.

During the second year, the eyes were treated with a treat- and-extend regimen.

Results.

Forty-four eyes were included.

Best-corrected visual acuity improved significantly after the loading phase (3.1 ± 6.4 letters) and at 6 months (2.8 ± 6.4 letters), but change was not significant at 1 year and 2 years.

The height of the DEP was significantly decreased at 3 months and 6 months, but the difference did not reach statistical difference at 1 and 2 years.

Rate of eyes with complete resolution of exudation was 59% after the loading phase and 34.3% at 2 years.

Mean interval of anti-VEGF injection was extended from 31 ± 2.6 days to 61 ± 5 days after conversion.

Conclusions.

Aflibercept intravitreal injection in patients with fibrovascular DEP due to nAMD who respond poorly to monthly ranibizumab led to short-term functional and anatomical improvement.

Reduction of intravitreal injection frequency was obtained until 2 years of follow-up.